These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

954 related items for PubMed ID: 16344520

  • 1. Predictors of relapse rate in MS clinical trials.
    Held U, Heigenhauser L, Shang C, Kappos L, Polman C, Sylvia Lawry Centre for MS Research.
    Neurology; 2005 Dec 13; 65(11):1769-73. PubMed ID: 16344520
    [Abstract] [Full Text] [Related]

  • 2. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ, Lederer C, Eder K, Daumer M, Neiss A, Polman C, Kappos L, Sylvia Lawry Centre for Multiple Sclerosis Research.
    Neurology; 2006 Sep 12; 67(5):804-8. PubMed ID: 16966541
    [Abstract] [Full Text] [Related]

  • 3. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
    Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
    [Abstract] [Full Text] [Related]

  • 4. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2007 Sep 18; 69(12):1230-5. PubMed ID: 17875911
    [Abstract] [Full Text] [Related]

  • 5. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.
    Neurology; 2007 Oct 09; 69(15):1498-507. PubMed ID: 17699802
    [Abstract] [Full Text] [Related]

  • 6. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 09; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 7. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H, Yinshan Zhao, Devonshire V.
    Mult Scler; 2008 Apr 09; 14(3):314-24. PubMed ID: 18208898
    [Abstract] [Full Text] [Related]

  • 8. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

  • 9. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec 10; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 10. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
    Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
    [Abstract] [Full Text] [Related]

  • 11. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 20; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 12. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB, Nyland HI, Aarseth JH, Riise T, Myhr KM.
    Mult Scler; 2009 Aug 20; 15(8):942-50. PubMed ID: 19570821
    [Abstract] [Full Text] [Related]

  • 13. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G, COGIMUS Study Group.
    Mult Scler; 2009 Jul 20; 15(7):779-88. PubMed ID: 19542262
    [Abstract] [Full Text] [Related]

  • 14. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Amato MP.
    J Neurol Sci; 2008 Mar 15; 266(1-2):25-30. PubMed ID: 17870094
    [Abstract] [Full Text] [Related]

  • 15. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
    Zivadinov R, Bagnato F, Nasuelli D, Bastianello S, Bratina A, Locatelli L, Watts K, Finamore L, Grop A, Dwyer M, Catalan M, Clemenzi A, Millefiorini E, Bakshi R, Zorzon M.
    J Neurol Sci; 2004 Aug 30; 223(2):185-93. PubMed ID: 15337621
    [Abstract] [Full Text] [Related]

  • 16. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R, Uxa L, Bratina A, Bosco A, Srinivasaraghavan B, Minagar A, Ukmar M, Benedetto Sy, Zorzon M.
    Int Rev Neurobiol; 2007 Aug 30; 79():521-35. PubMed ID: 17531857
    [Abstract] [Full Text] [Related]

  • 17. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD.
    J Neurol Sci; 2007 May 15; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [Abstract] [Full Text] [Related]

  • 18. A randomized crossover study of bee sting therapy for multiple sclerosis.
    Wesselius T, Heersema DJ, Mostert JP, Heerings M, Admiraal-Behloul F, Talebian A, van Buchem MA, De Keyser J.
    Neurology; 2005 Dec 13; 65(11):1764-8. PubMed ID: 16221950
    [Abstract] [Full Text] [Related]

  • 19. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C, Vukusic S.
    Brain; 2006 Mar 13; 129(Pt 3):606-16. PubMed ID: 16415308
    [Abstract] [Full Text] [Related]

  • 20. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.
    Ann Neurol; 2004 Oct 13; 56(4):548-55. PubMed ID: 15389896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.